Overview

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).
Phase:
Phase 1
Details
Lead Sponsor:
Nucorion Pharmaceuticals, Inc.
Collaborator:
Ligand Pharmaceuticals
Treatments:
Tenofovir